{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:10:48Z","timestamp":1792987848903,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Diabetes is an important cause of CKD. However, among people with diabetes, it is unclear to what extent CKD is attributable to diabetes itself versus comorbid conditions, such as advanced age and hypertension. We examined associations of diabetes with clinical manifestations of CKD independent of age and BP and the extent to which diabetes contributes to the overall prevalence of CKD in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      We performed a cross-sectional study of 15,675 participants in the National Health and Nutrition Examination Surveys from 2009 to 2014. Diabetes was defined by use of glucose-lowering medications or hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      \u22656.5%. eGFR was calculated using the CKD Epidemiology Collaboration formula, and albumin-to-creatinine ratio was measured in single-void urine samples. We calculated the prevalence of CKD manifestations by diabetes status as well as prevalence ratios, differences in prevalence, and prevalence attributable to diabetes using binomial and linear regression, incorporating data from repeat eGFR and urine albumin-to-creatinine ratio measurements to estimate persistent disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For participants with diabetes (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =2279) versus those without diabetes (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =13,396), the estimated prevalence of any CKD (eGFR&lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ; albumin-to-creatinine ratio \u226530 mg\/g, or both) was 25% versus 5.3%, respectively; albumin-to-creatinine ratio \u226530 mg\/g was 16% versus 3.0%, respectively; albumin-to-creatinine ratio \u2265300 mg\/g was 4.6% versus 0.3%, respectively; eGFR&lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      was 12% versus 2.5%, respectively; and eGFR&lt;30 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      was 2.4% versus 0.4%, respectively (each\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Adjusting for demographics and several aspects of BP, prevalence differences were 14.6% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), 10.8% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), 4.5% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), 6.5% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), and 1.8% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.004), respectively. Approximately 24% (95% confidence interval, 19% to 29%) of CKD among all United States adults was attributable to diabetes after adjusting for demographics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Diabetes is strongly associated with both albuminuria and reduced GFR independent of demographics and hypertension, contributing substantially to the burden of CKD in the United States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.03700417","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T11:37:07Z","timestamp":1508758627000},"page":"1984-1990","source":"Crossref","is-referenced-by-count":166,"title":["Diabetes and CKD in the United States Population, 2009\u20132014"],"prefix":"10.2215","volume":"12","author":[{"given":"Leila R.","family":"Zelnick","sequence":"first","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel S.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Epidemiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan R.","family":"Kestenbaum","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, and"},{"name":"Epidemiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassianne","family":"Robinson-Cohen","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, and"},{"name":"Epidemiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Heagerty","sequence":"additional","affiliation":[{"name":"Biostatistics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, and"},{"name":"Institute of Translational Health Sciences, University of Washington, Seattle, WA;"},{"name":"Providence Health Care, Spokane, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio N.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Medicine, Group Health Cooperative, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, and"},{"name":"Epidemiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"key":"B1-20230813","first-page":"83","article-title":"Intercapillary lesions in the glomeruli of the kidney.","volume":"12","author":"Kimmelstiel","year":"1936","journal-title":"Am J Pathol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States.","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014.","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis.","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes.","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: A report from an ADA Consensus Conference.","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"B8-20230813","first-page":"S88","article-title":"10. Microvascular complications and foot care.","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1753-0407.2010.00070.x","article-title":"Measurement of HbA1c from stored whole blood samples in the Atherosclerosis Risk in Communities study.","volume":"2","author":"Selvin","year":"2010","journal-title":"J Diabetes"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s001250050616","article-title":"Patterns of renal injury in NIDDM patients with microalbuminuria.","volume":"39","author":"Fioretto","year":"1996","journal-title":"Diabetologia"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ki.1992.118","article-title":"Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients.","volume":"41","author":"Parving","year":"1992","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1681\/ASN.V381458","article-title":"Heterogeneous nature of renal lesions in type II diabetes.","volume":"3","author":"Gambara","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"B17-20230813","first-page":"397","article-title":"Increased prevalence of renal biopsy findings other than diabetic glomerulopathy in type II diabetes mellitus.","volume":"7","author":"Richards","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function.","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI111523","article-title":"Structural-functional relationships in diabetic nephropathy.","volume":"74","author":"Mauer","year":"1984","journal-title":"J Clin Invest"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diabetes.52.4.1036","article-title":"Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions.","volume":"52","author":"Caramori","year":"2003","journal-title":"Diabetes"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.kint.2016.01.023","article-title":"An autopsy study suggests that diabetic nephropathy is underdiagnosed.","volume":"90","author":"Klessens","year":"2016","journal-title":"Kidney Int"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc06-0062","article-title":"Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.","volume":"29","author":"Cowie","year":"2006","journal-title":"Diabetes Care"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nrd.2016.67","article-title":"The next generation of therapeutics for chronic kidney disease.","volume":"15","author":"Breyer","year":"2016","journal-title":"Nat Rev Drug Discov"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201712000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:17Z","timestamp":1786369037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201712000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.03700417","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,20]]}}}